Michael Rucker - Mednax Independent Director
| MD Stock | USD 20.89 0.06 0.29% |
Insider
Michael Rucker is Independent Director of Mednax Inc since 2019.
| Age | 51 |
| Tenure | 7 years |
| Address | 1301 Concord Terrace, Sunrise, FL, United States, 33323 |
| Phone | 954 384 0175 |
| Web | https://www.pediatrix.com |
Mednax Management Efficiency
The company has Return on Asset (ROA) of 0.0686 % which means that for every $100 of assets, it generated a profit of $0.0686. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1998 %, which means that it produced $0.1998 on every 100 dollars invested by current stockholders. Mednax's management efficiency ratios could be used to measure how well Mednax manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.12. The current year's Return On Capital Employed is expected to grow to -0.04. At present, Mednax's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 211.4 M, whereas Other Current Assets are forecasted to decline to about 20.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ed Reisz | Aveanna Healthcare Holdings | 66 | |
| Christopher Hunter | Acadia Healthcare | 58 | |
| David Bourdon | Lifestance Health Group | 56 | |
| Kevin Ali | Organon Co | 65 | |
| Jeffrey Shaner | Aveanna Healthcare Holdings | 53 | |
| Joel Veit | Select Medical Holdings | N/A | |
| Felicia Gorcyca | Lifestance Health Group | 45 | |
| Beth Rubio | Aveanna Healthcare Holdings | 67 | |
| MD JD | Organon Co | 60 | |
| Patrick Cunningham | Aveanna Healthcare Holdings | 70 | |
| MD JD | Acadia Healthcare | N/A | |
| Tony Strange | Aveanna Healthcare Holdings | 61 | |
| J Abernathy | National HealthCare | 83 | |
| Robert Radics | Aveanna Healthcare Holdings | N/A | |
| Andrew Honeybone | Acadia Healthcare | N/A | |
| Kevin Mullins | Lifestance Health Group | 39 | |
| Pablo Pantaleoni | Lifestance Health Group | 36 | |
| Robby Stevenson | Addus HomeCare | 44 | |
| Vicki Dodson | National HealthCare | 64 | |
| Carl Adams | National HealthCare | N/A | |
| W Adams | National HealthCare | 73 | |
Management Performance
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0686 |
Mednax Inc Leadership Team
Elected by the shareholders, the Mednax's board of directors comprises two types of representatives: Mednax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mednax. The board's role is to monitor Mednax's management team and ensure that shareholders' interests are well served. Mednax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mednax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles CFA, Strategy Finance | ||
| Nanette Sanders, Executive Operations | ||
| Debra McRoberts, Senior Services | ||
| Enrique Sosa, Independent Director | ||
| Nikos Nikolopoulos, Executive Vice President Chief Strategy and Growth Officer | ||
| Michael Rucker, Independent Director | ||
| James MD, CEO Director | ||
| Paul Gabos, Independent Director | ||
| Pascal Goldschmidt, Independent Director | ||
| Roger Medel, Chief Executive Officer, Director | ||
| Cesar Alvarez, Independent Chairman of the Board | ||
| Dominic Andreano, Executive Vice President, General Counsel, Secretary | ||
| Mary Moore, Executive Vice President Chief Enterprise Risk and Legal Operations Officer | ||
| Mark Ordan, Chief Executive Officer, Director | ||
| Carlos Migoya, Independent Director | ||
| C Richards, Chief Financial Officer, Executive Vice President, Principal Accounting Officer | ||
| Kevin Pitzer, President Division | ||
| Linda Chen, President Operations | ||
| Stephen Farber, Chief Financial Officer, Executive Vice President | ||
| Michael MD, President Operations | ||
| John Pepia, Senior Vice President, Chief Accounting Officer | ||
| Jonathan Griffin, Integration Growth | ||
| John Starcher, Independent Director | ||
| Shirley Weis, Independent Director | ||
| Gregory Neeb, Executive Officer | ||
| Michael Lima, Senior Finance | ||
| Kasandra Rossi, Treasurer VP | ||
| CPC MBA, Senior Services | ||
| Waldemar Carlo, Independent Director | ||
| Mike Ashford, President Operations | ||
| Roger Hinson, President Pediatrix and Obstetrix Medical Group | ||
| Meghan Lublin, Chief VP | ||
| Manuel Kadre, Lead Independent Director | ||
| Michael Fernandez, Independent Director | ||
| Dana DreherRodwell, VP Officer | ||
| Suzanne Heck, President Market | ||
| Guy Sansone, Independent Chairman of the Board | ||
| Lee Wood, Executive Operations | ||
| Debra Kaspar, President Market | ||
| Roger MD, CoFounder Director | ||
| Cheryl VanPatten, Senior Officer | ||
| Karey Barker, Independent Director | ||
| Mary JD, Executive Officer | ||
| Marc Richards, Executive CFO | ||
| Thomas McEachin, Independent Director | ||
| Cheryl VanPattan, VP Officer | ||
| Curtis MD, Executive COO | ||
| Daniel Corcoran, Senior Care |
Mednax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mednax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0686 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 1.97 B | ||||
| Shares Outstanding | 85.88 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 97.90 % | ||||
| Number Of Shares Shorted | 3.04 M | ||||
| Price To Earning | 89.39 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Will Health Care Providers & Services sector continue expanding? Could Mednax diversify its offerings? Factors like these will boost the valuation of Mednax. Expected growth trajectory for Mednax significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mednax data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 2.652 | Earnings Share 1.91 | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets |
Understanding Mednax Inc requires distinguishing between market price and book value, where the latter reflects Mednax's accounting equity. The concept of intrinsic value - what Mednax's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Mednax's price substantially above or below its fundamental value.
Understanding that Mednax's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mednax represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Mednax's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.